Kentucky Retirement Systems Raises Holdings in Biogen Inc. $BIIB

Kentucky Retirement Systems lifted its position in Biogen Inc. (NASDAQ:BIIB) by 112.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,502 shares of the biotechnology company’s stock after purchasing an additional 10,331 shares during the quarter. Kentucky Retirement Systems’ holdings in Biogen were worth $3,575,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. LSV Asset Management grew its holdings in Biogen by 3.3% in the 4th quarter. LSV Asset Management now owns 316,815 shares of the biotechnology company’s stock valued at $55,756,000 after buying an additional 9,976 shares during the last quarter. Catalyst Funds Management Pty Ltd acquired a new stake in Biogen during the fourth quarter worth about $2,006,000. Orbimed Advisors LLC acquired a new stake in Biogen during the first quarter worth about $11,293,000. Systematic Financial Management LP increased its stake in Biogen by 256.3% during the fourth quarter. Systematic Financial Management LP now owns 16,640 shares of the biotechnology company’s stock valued at $2,928,000 after acquiring an additional 11,970 shares during the period. Finally, Contrarius Group Holdings Ltd acquired a new position in Biogen in the 4th quarter valued at approximately $11,431,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on BIIB shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Biogen in a report on Monday, June 22nd. Barclays upped their target price on Biogen from $185.00 to $200.00 and gave the company an “equal weight” rating in a research note on Wednesday. Wall Street Zen upgraded shares of Biogen from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Citigroup boosted their price target on shares of Biogen from $190.00 to $200.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Finally, Argus raised shares of Biogen to a “hold” rating in a report on Thursday, April 9th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $223.36.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q2 results exceeded expectations: Biogen reported approximately $2.74 billion in revenue, up 3.4% year over year and above the $2.46 billion consensus estimate. Adjusted EPS of $3.60 also topped forecasts near $2.94, supported by stronger rare-disease and newer-product sales. Biogen beats quarterly estimates as newer drugs fuel growth
• Positive Sentiment: Growth portfolio is offsetting legacy weakness: Revenue from Biogen’s Growth Portfolio rose 24% to about $1.06 billion, surpassing its legacy multiple sclerosis portfolio. The Apellis acquisition added sales from SYFOVRE and EMPAVELI, while products including SKYCLARYS and ZURZUVAE contributed to momentum. Biogen’s Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance Raised
• Positive Sentiment: Analyst sentiment improved: TD Cowen raised its price target to $225 and assigned a Buy rating, while Morgan Stanley lifted its target to $231 and maintained Equal Weight. Wedbush also raised its target to $215, and Piper Sandler reaffirmed its Buy rating. Analyst target updates
• Neutral Sentiment: 2026 outlook was updated: Biogen expects full-year non-GAAP EPS of $12 to $13 and mid-single-digit revenue growth. The revenue outlook benefits from the newer portfolio, but the EPS range is below the roughly $13.45 analyst consensus, partly reflecting acquisition-related costs. Biogen beats quarterly estimates as newer drugs fuel growth
• Negative Sentiment: Reported profitability deteriorated materially: GAAP net income fell to $97.5 million from $634.8 million a year earlier, while diluted EPS dropped to $0.66 from $4.33. Legacy multiple sclerosis sales also remained under pressure, and Leqembi sales narrowly missed expectations. Biogen profitability compression

Biogen Price Performance

Biogen stock opened at $207.93 on Friday. Biogen Inc. has a 52 week low of $124.56 and a 52 week high of $219.72. The business’s fifty day moving average is $201.05 and its two-hundred day moving average is $190.52. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.41 and a current ratio of 1.87. The firm has a market cap of $30.70 billion, a P/E ratio of 36.80 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The company had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. During the same period in the previous year, the firm posted $5.47 earnings per share. The company’s revenue was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities research analysts forecast that Biogen Inc. will post 12.38 earnings per share for the current fiscal year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.